ClinicalTrials.gg
CompletedNCT05841966OP-CUPUpdated May 7, 2024

Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown Primary

An interventional study of Transoral Ultrasound in Cancer of Unknown Primary Site, Unknown Primary Cancer and Unknown Primary, Squamous Cell Carcinoma, sponsored by Rigshospitalet, Denmark. Completed at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-07.

Sponsored by Rigshospitalet, Denmark · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Adult patients suspected of Squamous Cell Carcinoma of Unknown Primary (SCCUP) will be prospectively enrolled at a tertiary head \& neck cancer center at Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. All patients will undergo Magnetic Resonance Imaging (MRI) and Positron Emission Tomography-Computerized Tomography (PET-CT) prior to examination in general anesthesia. During general anesthesia, Intraoperative Transoral Ultrasound (ITUS) will be performed prior to panendoscopy. Detected tumors will be registered with specified oropharyngeal sub-locations. Blinded to ITUS, a consultant head \& neck surgeon will perform panendoscopy. After examination, the surgeon is unblinded to ultrasound results. Final histopathology results from location-specified biopsies performed will be used as reference standard. The overall detection rate will be compared between ITUS, panendoscopy, PET-CT and MRI with sensitivity and specificity analysis. Oropharynx sub-location specific detection rate of ITUS vs. panendoscopy will be compared with logistic regression analysis.

Read the detailed description

A prospective diagnostic study examining patients with suspected SCCUP will be performed at the Department of Otorhinolaryngology \& Head \& Neck Surgery, Copenhagen University Hospital - Rigshospitalet, Denmark. This specialized cancer center is responsible for the surgical work-up for approximately half of suspected SCCUP patients in the Danish population of 5.8 million.

Standard work-up of patients with suspected SCCUP in Denmark consists of same-day clinical examination combined with high resolution video endoscopy with NBI, surgeon-performed neck ultrasound and fine-needle aspiration cytology (FNAC) of suspected lymph nodes with same-day results. Cytology results can be further tested for Human Papillomavirus (HPV), and patients are booked for panendoscopic examination under general anesthesia with frozen section biopsy. Pre-operative cross-sectional imaging to locate the primary tumor includes MRI and 18-F Fluordeoxyglucose (FDG) PET-CT.

Intraoperative transoral ultrasound

During general anesthesia and prior to panendoscopy, ITUS will be performed while a consultant head \& neck surgeon performing panendoscopy is blinded. A Fujifilm Arietta 850 or Arietta 65 (Fujifilm, Tokyo, Japan), BK5000 (BK Medical ApS, Herlev, Denmark), or Samsung RS85 (Samsung Medison, Seoul, South Korea) ultrasound machines will be used. Small-footprint, high-frequency transducers such as the Arietta L51K linear-array intraoperative robot transducer attached to a forceps, the BK5000 "flexible hockey-stick" 18XL5s, or the Samsung RS85 LA3-22AI "hockeystick" will be used. A Boyle-Davis gag or laryngoscope will be used to visualize the tonsils (Figure 1), while the transducer is placed onto each tonsil in transverse and sagittal planes. The tongue base will be scanned by pulling the tongue anteriorly by an assistant and placing the transducer directly onto the tongue base. Alternatively, the tongue can be retracted with a video-laryngoscope while revealing the tongue base. The tongue base will be scanned from side to side in the sagittal plane. The tongue can then be pulled to either the left or right side to angle the probe obliquely for transverse imaging. If a tumor is suspected, the tumor location is registered in the following categories, including indication of right or left side:

  • Tonsil cranial.
  • Tonsil caudal.
  • Glossotonsillar sulcus.
  • Anterolateral tongue base.
  • Anteromedial tongue base.
  • Posterolateral tongue base.
  • Posteromedial tongue base.
  • "Other" oropharynx sub-locations, including anterior \& posterior pharyngeal arches, soft palate, uvula, posterior oropharynx wall, and vallecula.

B-mode video clips of both tonsils and the tongue base will be recorded. Power doppler for suspected tumors and the contralateral side will be performed. If a well-defined lesion is seen, the greatest tumor diameter and if possible, three-dimensional size is measured. The grade of tumor suspicion will be rated on a 5-point Likert scale ranging from 0 (very low) to 5 (very high).

Panendoscopy Following ITUS, the surgeon will perform standard panendoscopy of the pharynx including palpation of the oral cavity and oropharynx, and high-resolution video endoscopy with NBI. If the surgeon suspects a tumor, the location is registered with the same categories as above. Tumor suspicion will be rated on a 5-point Likert scale ranging from 0 (very low) to 5 (very high). The surgeon will categorize visual findings such as ulcers, exophytic tumors, asymmetric tissue, vulnerable/bleeding mucosa, suspect vasculature on NBI, or no suspect visual findings. The surgeon will categorize palpatory findings as soft or firm. The clinically visualized or palpated greatest tumor diameter will be estimated. The surgeon is then unblinded to ultrasound results. After unblinding from ultrasound, the investigators will register whether further directed biopsies from ultrasound suspected location are performed.

If the primary tumor is not located during panendoscopy, patients will tonsillectomied and the tonsils will be sliced in 2mm slices by head \& neck pathologists in search of the primary tumor. If the primary tumor is still unknown and the neck metastasis is HPV+, then patients are offered Transoral Robotic Surgery (TORS) with diagnostic tongue base mucosectomy. These tongue base specimens will also be sliced in 2mm slices and examined by head \& neck pathologists. If the primary tumor is located in final histopathology from either tonsillectomies or tongue base mucosectomy, the location of the tumors will be compared to the initially registered suspected ultrasound locations from panendoscopy.

Medical chart data The patient's age, sex, alcohol, smoking, largest cervical lymph node size, cervical lymph node side (right/left), date of panendoscopy, date of conclusive histopathology results, and date of treatment initiation will be obtained from medical charts.

02

Conditions studied

  • Cancer of Unknown Primary Site
  • Unknown Primary Cancer
  • Unknown Primary, Squamous Cell Carcinoma
03

In context

Neoplasms, Unknown Primary

101 studies on the registry are indexed under Neoplasms, Unknown Primary; 19 are open to participants now.

This study's enrollment of 30 is below the median of 52 across 63 interventional studies indexed under Neoplasms, Unknown Primary.

Browse Neoplasms, Unknown Primary studies →

Lead sponsor

Rigshospitalet, Denmark is the lead sponsor of 1,007 studies on the registry; 175 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cytology-verified cervical lymph node from squamous cell carcinoma in neck levels I-IV with HPV+ cytology.
  • Booked for panendoscopic examination under general anesthesia.
  • Pre-operative MRI and PET-CT available.

Exclusion criteria

Exclusion Criteria:

  • Unable to provide written .
  • Unable to complete full surgical work-up including palatine- and lingual tonsillectomy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Intraoperative Transoral Ultrasound

    Transoral ultrasound of the tonsils and tongue base under general anesthesia.

    Diagnostic Test: Transoral Ultrasound

Interventions

  • Diagnostic testTransoral Ultrasound

    The tonsils and tongue base will be scanned transorally using high-frequency intraoperative ultrasound transducers. Direct contact with the tonsils through the mouth is achieved during general anesthesia.

06

What researchers measure

Primary outcomes

  1. Increased detection rate by adding ITUS to panendoscopy

    The difference in proportion of patients with SCCUP where a primary tumor location is correctly detected by ITUS but not detected with panendoscopy alone.

    Time frame: Within 2-4 weeks after panendoscopy.

Secondary outcomes

  1. Ultrasonographic features of primary tonsil and tongue base tumors

    The echogenicity, shape and doppler flow pattern relative to the normal and contralateral tonsil tissue will be compared in biopsy-verified primary tumors.

    Time frame: 1 year

  2. Comparison of detection rate of ITUS, panendoscopy, combined ITUS+panendoscopy, MRI and PET-CT for locating the primary tumor.

    The percentage of primary tumors located is compared between all of the above tests.

    Time frame: 1 year

Other outcomes

  1. Average time in minutes used to perform transoral ultrasound

    Average operative time, including setup with mouth gags, to perform transoral ultrasound in general anesthesia.

    Time frame: 1 year

07

Study locations

2 sites
  • Rigshospitalet, Department of Otorhinolaryngology, Head & Neck Surgery & Audiology
    Copenhagen, 2100, Denmark
  • Århus University Hospital, Department of Otorhinolaryngology, Head & Neck Surgery
    Århus, 8200, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05841966
Collaborators
The Novo Nordic Foundation
Responsible party
Martin Garset-Zamani, MD (Principal Investigator, Rigshospitalet, Denmark) — Principal investigator
First posted
May 3, 2023
Start date
Feb 21, 2023
Primary completion
Jan 29, 2024
Completion
Mar 1, 2024
Last update
May 7, 2024

Study contacts

Tobias Todsen, MD, PhD
study director · Rigshospitalet, Denmark

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion